IP Library Patent Application 16212534
Patent Application
App. No. 16/212,534

PEG-MEDIATED ASSEMBLY OF NUCLEIC ACID MOLECULES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/212,534
Abstract

The present invention discloses methods for assembling a nucleic acid molecule from a set of overlapping oligonucleotides. The method involves contacting a set of overlapping oligonucleotides with a DNA polymerase, a mixture of dNTPs, and a crowding agent to form an assembly mixture. In one embodiment the crowding agent is polyethylene glycol (PEG). The presence of the crowding agent facilitates the nucleic acid assembly process of the invention. The assembly mixture is then subjected to multiple cycles, each cycle comprising an annealing phase, an extension phase, and a denaturation phase, and the desired nucleic acid molecule is thereby assembled. In some embodiments one or more of the phases are time varied.

Claims (50)

1 . A method for assembling a nucleic acid molecule in a single step from a set of overlapping oligonucleotides, the method comprising:

(a) combining a set of at least 5 overlapping oligonucleotides with

a DNA polymerase;

a mixture of dNTPs; and

polyethylene glycol at a concentration of greater than 0.0188%;

in a reaction vessel to form an assembly mixture;

(b) subjecting the assembly mixture to at least 25 cycles, each cycle comprising

an annealing phase performed at between 50° C. and 77° C.;

an extension phase performed at between 50° C. and 77° C., and

a denaturation phase performed at greater than 90° C.;

(c) thereby assembling the nucleic acid molecule from a set of overlapping oligonucleotides in a single step.

2 . The method of claim 1 wherein the set of oligonucleotides comprises end oligonucleotides and non-end oligonucleotides, and the end oligonucleotides are provided in the assembly mixture at a higher concentration than the non-end oligonucleotides.

3 . The method of claim 1 wherein the extension phase of a cycle is increased in time relative to the extension phase of the previous cycle.

4 . The method of claim 1 wherein the DNA polymerase is a DNA polymerase from Pyrococcus furiosus modified to have a processivity enhanced domain relative to native Pyrococcus furiosus DNA polymerase.

5 . The method of claim 1 wherein the polyethylene glycol is PEG 8000.

6 . The method of claim 5 wherein the concentration of PEG in the assembly mixture is 0.025% or greater.

7 . The method of claim 1 wherein the concentration of PEG in the assembly mixture is 0.375% or greater.

8 . The method of claim 7 wherein the nucleic acid molecule is greater than 1 kb in length.

9 . The method of claim 8 wherein the nucleic acid molecule is greater than 2 kb in length.

10 . The method of claim 9 wherein the nucleic acid molecule is greater than 3 kb in length.

11 . The method of claim 1 wherein the set of overlapping oligonucleotides comprises at least 10 oligonucleotides.

12 . The method of claim 12 wherein the set of overlapping oligonucleotides comprises at least 60 oligonucleotides.

13 . The method of claim 12 wherein the set of overlapping oligonucleotides comprises at least 75 oligonucleotides.

14 . The method of claim 13 comprising more than 25 cycles that comprise an annealing phase, an extension phase, and a denaturation phase, and wherein the nucleic acid molecule assembled is greater than 2 kb, the initial extension phase is between 5 minutes and 7 minutes, and subsequent extension phases are time varied phases.

15 . The method of claim 14 wherein the nucleic acid molecule assembled is greater than 3 kb, the initial extension phase is between 5 minutes and 7 minutes, and subsequent extension phases are progressively increased in time relative to the initial extension phase.

16 . The method of claim 15 wherein the set of overlapping nucleotides comprises more than 100 oligonucleotides.

17 . The method of claim 1 wherein the extension phase is a time varied phase.

18 . The method of claim 17 wherein the extension phase is cumulatively extended by about 15 seconds per cycle.

19 . The method of claim 1 wherein the multiple cycles comprise at least 30 cycles.

20 . The method of claim 1 wherein the nucleic acid molecule assembled comprises one or more AT rich sequences.

21 . The method of claim 1 wherein the oligonucleotides have a length selected from the group consisting of: 20-40 nucleotides, 30-50, 40-60, 50-70, and 60-80 nucleotides; and the nucleic acid assembled is greater than 1 kb.

22 . The method of claim 19 wherein the nucleic acid assembled is greater than 3 kb.

23 . A method for assembling a nucleic acid molecule in a single step from a set of overlapping oligonucleotides, the method comprising:

(a) combining a set of at least 5 overlapping oligonucleotides with

a DNA polymerase;

a mixture of dNTPs; and

polyethylene glycol at a concentration of greater than 0.0188%;

in a reaction vessel to form an assembly mixture;

(b) subjecting the assembly mixture to at least 25 cycles, each cycle comprising

a combined annealing and extension phase performed at a temperature between 50° C. and 77° C., and

a denaturation phase performed at greater than 90° C., but at a temperature different from and higher than the annealing and extension phase;

(c) thereby assembling the nucleic acid molecule from a set of overlapping oligonucleotides in a single step.

24 . The method of claim 23 wherein the combined annealing and extension phase is performed at about 67° C.

25 . The method of claim 28 wherein the combined annealing and extension phase, is performed at between 57° C. and 77° C.

26 . The method of claim 1 wherein

the set of overlapping oligonucleotides comprises at least 25 overlapping oligonucleotides; and

the polyethylene glycol is present at a concentration of greater than 0.375%.

27 . The method of claim 29 wherein the denaturation phase is performed at about 98° C.

28 . The method of claim 29 wherein the oligonucleotides have a length selected from the group consisting of: 20-40 nucleotides, 30-50, 40-60, 50-70, and 60-80 nucleotides; and the nucleic acid assembled is greater than 1 kb.

29 . The method of claim 1 wherein the concentration of PEG in the assembly mixture is greater than 0.0188% and less than 1.0%.

Assignments (7)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (REVOLVING) Recorded Jul 16, 2024
From: MIDCAP FUNDING IV TRUST
To: TELESIS BIO INC. (FORMERLY KNOWN AS CODEX DNA, INC.); ETONBIO, INC.
Reel/Frame 068390/0001 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (TERM) Recorded Jul 16, 2024
From: MIDCAP FINANCIAL TRUST
To: TELESIS BIO INC. (FORMERLY KNOWN AS CODEX DNA, INC.); ETONBIO, INC.
Reel/Frame 068390/0070 →
SECURITY INTEREST (REVOLVING) Recorded Aug 18, 2022
From: CODEX DNA, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 061208/0063 →
SECURITY INTEREST (TERM) Recorded Aug 18, 2022
From: CODEX DNA, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061208/0080 →
RELEASE OF SECURITY INTEREST Recorded Nov 10, 2020
From: OXFORD FINANCE LLC
To: SYNTHETIC GENOMICS, INC.; GENOVIA BIO, LLC; GREEN RESOURCES, LLC; SGI-DNA, INC.; SYNTHETIC GENOMICS VACCINES, INC.
Reel/Frame 054372/0822 →
CHANGE OF NAME Recorded May 19, 2020
From: SGI-DNA, INC.
To: CODEX DNA, INC.
Reel/Frame 052705/0893 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2019
From: SYNTHETIC GENOMICS, INC.
To: SGI-DNA, INC.
Reel/Frame 049602/0502 →